

Achaogen
 Investor Relations Department
 7000 Shoreline Court,
 3rd Floor
 South San Francisco, CA 94080
 United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AKAO

Last Trade:	11.54
Trade Time:	4:00 PM ET Jan 19, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	10.24 - 27.79
Volume	69

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments against multi-drug resistant (MDR), gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI), bloodstream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). In 2013, the Centers for Disease Control and Prevention identified CRE... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 3, 2018*
[Achaogen to Present at J.P. Morgan Healthcare Conference](#)
- Jan 2, 2018*
[Achaogen Announces FDA Acceptance of New Drug Application with Priority Review for Plazomicin for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections](#)
- Jan 2, 2018*
[Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scap](#)
- Dec 22, 2017*
[Achaogen Announces New Employment Inducement Grants](#)
- Dec 11, 2017*
[Achaogen Appoints Blake Wise Chief Executive Officer](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 14, 2017*
[Annual Report \(10-K\)](#)
- Apr 26, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)